Literature DB >> 19474477

Investigation of expert rule bases, logistic regression, and non-linear machine learning techniques for predicting response to antiretroviral treatment.

Mattia C F Prosperi1, Andre Altmann, Michal Rosen-Zvi, Ehud Aharoni, Gabor Borgulya, Fulop Bazso, Anders Sönnerborg, Eugen Schülter, Daniel Struck, Giovanni Ulivi, Anne-Mieke Vandamme, Jurgen Vercauteren, Maurizio Zazzi.   

Abstract

BACKGROUND: The extreme flexibility of the HIV type-1 (HIV-1) genome makes it challenging to build the ideal antiretroviral treatment regimen. Interpretation of HIV-1 genotypic drug resistance is evolving from rule-based systems guided by expert opinion to data-driven engines developed through machine learning methods.
METHODS: The aim of the study was to investigate linear and non-linear statistical learning models for classifying short-term virological outcome of antiretroviral treatment. To optimize the model, different feature selection methods were considered. Robust extra-sample error estimation and different loss functions were used to assess model performance. The results were compared with widely used rule-based genotypic interpretation systems (Stanford HIVdb, Rega and ANRS).
RESULTS: A set of 3,143 treatment change episodes were extracted from the EuResist database. The dataset included patient demographics, treatment history and viral genotypes. A logistic regression model using high order interaction variables performed better than rule-based genotypic interpretation systems (accuracy 75.63% versus 71.74-73.89%, area under the receiver operating characteristic curve [AUC] 0.76 versus 0.68-0.70) and was equivalent to a random forest model (accuracy 76.16%, AUC 0.77). However, when rule-based genotypic interpretation systems were coupled with additional patient attributes, and the combination was provided as input to the logistic regression model, the performance increased significantly, becoming comparable to the fully data-driven methods.
CONCLUSIONS: Patient-derived supplementary features significantly improved the accuracy of the prediction of response to treatment, both with rule-based and data-driven interpretation systems. Fully data-driven models derived from large-scale data sources show promise as antiretroviral treatment decision support tools.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19474477

Source DB:  PubMed          Journal:  Antivir Ther        ISSN: 1359-6535


  19 in total

1.  A Rough Set-Based Model of HIV-1 Reverse Transcriptase Resistome.

Authors:  Marcin Kierczak; Krzysztof Ginalski; Michał Dramiński; Jacek Koronacki; Witold Rudnicki; Jan Komorowski
Journal:  Bioinform Biol Insights       Date:  2009-10-05

2.  Comparison of HIV-1 genotypic resistance test interpretation systems in predicting virological outcomes over time.

Authors:  Dineke Frentz; Charles A B Boucher; Matthias Assel; Andrea De Luca; Massimiliano Fabbiani; Francesca Incardona; Pieter Libin; Nino Manca; Viktor Müller; Breanndán O Nualláin; Roger Paredes; Mattia Prosperi; Eugenia Quiros-Roldan; Lidia Ruiz; Peter M A Sloot; Carlo Torti; Anne-Mieke Vandamme; Kristel Van Laethem; Maurizio Zazzi; David A M C van de Vijver
Journal:  PLoS One       Date:  2010-07-09       Impact factor: 3.240

3.  Antiretroviral therapy optimisation without genotype resistance testing: a perspective on treatment history based models.

Authors:  Mattia C F Prosperi; Michal Rosen-Zvi; André Altmann; Maurizio Zazzi; Simona Di Giambenedetto; Rolf Kaiser; Eugen Schülter; Daniel Struck; Peter Sloot; David A van de Vijver; Anne-Mieke Vandamme; Anders Sönnerborg
Journal:  PLoS One       Date:  2010-10-29       Impact factor: 3.240

4.  Lopinavir Resistance Classification with Imbalanced Data Using Probabilistic Neural Networks.

Authors:  Letícia M Raposo; Mônica B Arruda; Rodrigo M de Brindeiro; Flavio F Nobre
Journal:  J Med Syst       Date:  2016-01-06       Impact factor: 4.460

5.  Sparse Representation for Prediction of HIV-1 Protease Drug Resistance.

Authors:  Xiaxia Yu; Irene T Weber; Robert W Harrison
Journal:  Proc SIAM Int Conf Data Min       Date:  2013

6.  Investigation of Super Learner Methodology on HIV-1 Small Sample: Application on Jaguar Trial Data.

Authors:  Allal Houssaïni; Lambert Assoumou; Anne Geneviève Marcelin; Jean Michel Molina; Vincent Calvez; Philippe Flandre
Journal:  AIDS Res Treat       Date:  2012-04-03

7.  Predictors of first-line antiretroviral therapy discontinuation due to drug-related adverse events in HIV-infected patients: a retrospective cohort study.

Authors:  Mattia C F Prosperi; Massimiliano Fabbiani; Iuri Fanti; Mauro Zaccarelli; Manuela Colafigli; Annalisa Mondi; Alessandro D'Avino; Alberto Borghetti; Roberto Cauda; Simona Di Giambenedetto
Journal:  BMC Infect Dis       Date:  2012-11-12       Impact factor: 3.090

8.  A prognostic model for estimating the time to virologic failure in HIV-1 infected patients undergoing a new combination antiretroviral therapy regimen.

Authors:  Mattia C F Prosperi; Simona Di Giambenedetto; Iuri Fanti; Genny Meini; Bianca Bruzzone; Annapaola Callegaro; Giovanni Penco; Patrizia Bagnarelli; Valeria Micheli; Elisabetta Paolini; Antonio Di Biagio; Valeria Ghisetti; Massimo Di Pietro; Maurizio Zazzi; Andrea De Luca
Journal:  BMC Med Inform Decis Mak       Date:  2011-06-14       Impact factor: 2.796

9.  Clinical evaluation of Rega 8: an updated genotypic interpretation system that significantly predicts HIV-therapy response.

Authors:  Jurgen Vercauteren; Gertjan Beheydt; Mattia Prosperi; Pieter Libin; Stijn Imbrechts; Ricardo Camacho; Bonaventura Clotet; Andrea De Luca; Zehava Grossman; Rolf Kaiser; Anders Sönnerborg; Carlo Torti; Eric Van Wijngaerden; Jean-Claude Schmit; Maurizio Zazzi; Anna-Maria Geretti; Anne-Mieke Vandamme; Kristel Van Laethem
Journal:  PLoS One       Date:  2013-04-17       Impact factor: 3.240

10.  Scoring methods for building genotypic scores: an application to didanosine resistance in a large derivation set.

Authors:  Allal Houssaini; Lambert Assoumou; Veronica Miller; Vincent Calvez; Anne-Geneviève Marcelin; Philippe Flandre
Journal:  PLoS One       Date:  2013-03-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.